The ATM kinase inhibitor KU-55933, which targets ATMs involved in the DNA damage response pathway, is in preclinical development [144]; FANCL, part of the Fanconi anemia DNA repair pathway, has been targeted by small molecule inhibitors, such as curcumin, in preclinical studies [145]; and CDK5 inhibitors, like roscovitine and dinaciclib, have shown promise in preclinical studies and are in clinical trials for various cancer types [146]. Here, FANCL is linked to Fanconi anemia.